Clopidogrel is FDA approved for the medical management of unstable angina (UA)/non-ST-segment elevation myocardial infarction (NSTEMI), ST-segment elevation myocardial infarction (STEMI) in patients receiving fibrinolytic therapy, and for secondary prevention in recent myocardial infarction (MI), recent stroke, and peripheral arterial disease.

FDA-approved indications for clopidogrel include:

- Use during aÂ percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) and stable ischemic heart disease.

- Primary prevention of thromboembolism atrial fibrillation

- Symptomatic carotid artery stenosis

- Secondary prevention post-coronary artery bypass grafting

- Peripheral artery percutaneous angioplasty in peripheral artery bypass grafting